Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Abiraterone is approved in the United States by the U.S. Food and Drug Administration (FDA)
to treat metastatic prostate cancer at 1000 mg daily.
The purpose of this study is to find out if an on and off schedule of taking abiraterone
would prolong the participant's cancer's response to this drug and maintain their
functionality to perform their daily activities.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute